The Utility of Food-Specific IgE Measured With the IMMULITE 2000 Assay to Predict Symptomatic Food Allergy

Inclusion Criteria: * Age 3 to 21 years of either sex and any race * Physician-diagnosed food allergy or convincing clinical history of food allergy to milk, egg, and/or peanut AND a Skin prick test positive to milk, egg, and/or peanut (diameter of wheal \> 3 mm or greater than negative control) orOR a detectable serum food-specific IgE level (ImmunoCAP and/or IMMULITE \> 0.35 kUA/L) to milk, egg, and/or peanut * If no history of clinical reactivity to milk, egg, or peanut, then a positive skin prick test to milk, egg, and/or peanut (diameter of wheal \> 3 mm or greater than negative control) OR a detectable serum food-specific IgE level within the previous 4 months to milk, egg, and/or peanut * Written informed consent from parent/guardian and assent (when age appropriate). * Willingness to submit specimen for laboratory serum IgE testing Exclusion Criteria: * Inability to discontinue antihistamines for skin prick testing and OFCs * Current allergy to placebo ingredient (oat flour) OR reaction to any dose of placebo at the qualifying OFC * FEV1 value \<80% predicted OR any clinical features of moderate or severe persistent asthma, as defined by the 2007 NHLBI guidelines table for classifying asthma baseline severity (Step 3 or above), at the time of entry into the study * Use of , and \>high medium daily doses of inhaled corticosteroids, as defined by the 2007 NHLBI guidelines inhaled corticosteroid dosing table (500500 μg/day fluticasone or equivalents for an adult) or a long acting beta-agonist (LABA) to control asthma. * Asthma requiring either: \> 1 hospitalization in the past year for asthma or \> 1 ER visit in the past 6 months for asthma * History of intubation due to allergies or asthma * Use of steroid medications (IV, IM or oral) for asthma in the following manners: * history of daily oral steroid dosing for \>1 month during the past year or * burst or steroid course/burst in the past 3 months or * \>2 burst oral steroid courses/bursts in the past year * History of intubation due to allergies or asthma * Life-threatening allergic reaction (e.gi.e., respiratory compromise, hypoxia, hypotension, use of epinephrine) to study food(s) (e.g., milk, egg, and/or peanut) within last 1 year * Diagnosis of active eosinophilic gastrointestinal disease in the past year * Severe or poorly controlled atopic dermatitis, as assessed by a three-item severity (TIS) score of 6 or greater (see Appendix I) * Use of omalizumab or other non-traditional forms of allergen immunotherapy (e.g., oral or sublingual), immunomodulatory therapy (not including corticosteroids), or biologic therapy within the past year * Uncontrolled hypertension * Any use of β-blockers (oral), angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARB) or calcium channel blockers * Other significant medical conditions (e.g., liver, gastrointestinal, kidney, cardiovascular, pulmonary disease, or blood disorders), which, in the opinion of the Investigator, make the subject unsuitable for induction of food reactions * Pregnancy